Companion Diagnostics for Targeted Therapies
Tempus offers companion diagnostic development across our portfolio of assays, leveraging a broad-panel, universal platform used by thousands of oncologists globally. These assays can each incorporate multiple companion diagnostic markers, providing value across biopharma portfolios.
TEMPUS ADVANTAGES
Save time
Tempus provides an established, validated platform to reduce development time and cost associated with companion diagnostic approval.
Improve program success
As one of the leaders pioneering real-world data, Tempus’ robust clinico-genomics database can be used in tandem with trial sequencing data to set up control arms, compare trial data to real-world data, and generate clinically-meaningful comparator data throughout the trial. Tempus’ sequencing data covers DNA tumor/normal, RNA transcriptome, and key immunotherapy metrics, allowing for a more holistic view to stratify likely responders.
Immediate commercialization
Companion diagnostic markers will be incorporated into assays already being used today by thousands of oncologists. Tempus provides a seamless commercialization and reimbursement strategy at launch.